133 related articles for article (PubMed ID: 22702065)
1. Screening at 11-13+6 weeks' gestation.
Sonek JD; Nicolaides KH; Janku P
Ceska Gynekol; 2012 Apr; 77(2):92-104. PubMed ID: 22702065
[TBL] [Abstract][Full Text] [Related]
2. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
[TBL] [Abstract][Full Text] [Related]
3. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
[TBL] [Abstract][Full Text] [Related]
4. Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation.
Spencer K; Yu CK; Savvidou M; Papageorghiou AT; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Jun; 27(6):658-63. PubMed ID: 16493628
[TBL] [Abstract][Full Text] [Related]
5. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
Chen X; Chang Y; Cui HY; Ren CC; Yu BY
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
[TBL] [Abstract][Full Text] [Related]
6. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Hoopmann M; Abele H; Alkier R; Lüthgens K
Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
[TBL] [Abstract][Full Text] [Related]
7. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
[TBL] [Abstract][Full Text] [Related]
8. Aneuploidy screening in the first trimester.
Spencer K
Am J Med Genet C Semin Med Genet; 2007 Feb; 145C(1):18-32. PubMed ID: 17290444
[TBL] [Abstract][Full Text] [Related]
9. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
10. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency.
Orlandi F; Damiani G; Hallahan TW; Krantz DA; Macri JN
Ultrasound Obstet Gynecol; 1997 Dec; 10(6):381-6. PubMed ID: 9476320
[TBL] [Abstract][Full Text] [Related]
11. First-trimester screening for early and late small-for-gestational-age neonates using maternal serum biochemistry, blood pressure and uterine artery Doppler.
Crovetto F; Crispi F; Scazzocchio E; Mercade I; Meler E; Figueras F; Gratacos E
Ultrasound Obstet Gynecol; 2014 Jan; 43(1):34-40. PubMed ID: 23754253
[TBL] [Abstract][Full Text] [Related]
12. First-trimester nuchal translucency screening for fetal aneuploidy.
Sherer DM; Manning FA
Am J Perinatol; 1999; 16(3):103-20. PubMed ID: 10438192
[TBL] [Abstract][Full Text] [Related]
13. [Performance of different methods of estimating risk screening for chromosomal anomalies].
Avătăjitei MC; Moscalu M; Martiniuc V; Onofriescu M
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):515-22. PubMed ID: 23077946
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing visualization of the intracranial translucency during first-trimester screening for aneuploidy.
Beamon CJ; Stuebe AM; Wolfe HM
Am J Perinatol; 2012 Aug; 29(7):503-8. PubMed ID: 22495902
[TBL] [Abstract][Full Text] [Related]
15. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
[TBL] [Abstract][Full Text] [Related]
16. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
Spencer K; Nicolaides KH
BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
[TBL] [Abstract][Full Text] [Related]
17. First trimester contingent testing with either nuchal translucency or cell-free DNA. Cost efficiency and the role of ultrasound dating.
Conner P; Gustafsson S; Kublickas M
Acta Obstet Gynecol Scand; 2015 Apr; 94(4):368-75. PubMed ID: 25581307
[TBL] [Abstract][Full Text] [Related]
18. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia.
Spencer K; Cowans NJ; Chefetz I; Tal J; Meiri H
Ultrasound Obstet Gynecol; 2007 Feb; 29(2):128-34. PubMed ID: 17149788
[TBL] [Abstract][Full Text] [Related]
19. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
[TBL] [Abstract][Full Text] [Related]
20. First-trimester screening: an overview.
Eiben B; Glaubitz R
J Histochem Cytochem; 2005 Mar; 53(3):281-3. PubMed ID: 15750002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
